Amylyx Pharmaceuticals, Inc. (AMLX)

34.74 -6.56% (-2.44)

Over 1M: +71.0%

2026-08-28
20 30 40
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '21 — Revenue: 285K Q3 '21 — Operating Cash Flow: -20.9M Q3 '21 — Free Cash Flow: -21M Q3 '21 — Net Income: -23.1M Q4 '21 — Revenue: 0 Q4 '21 — Operating Cash Flow: -28.2M Q4 '21 — Free Cash Flow: -28.4M Q4 '21 — Net Income: -28.3M Q1 '22 — Operating Cash Flow: -40.6M Q1 '22 — Free Cash Flow: -41M Q1 '22 — Net Income: -47.8M Q2 '22 — Operating Cash Flow: -46.5M Q2 '22 — Free Cash Flow: -47.6M Q2 '22 — Net Income: -54.1M Q3 '22 — Revenue: 345K Q3 '22 — Operating Cash Flow: -43.1M Q3 '22 — Free Cash Flow: -43.5M Q3 '22 — Net Income: -53.8M Q4 '22 — Revenue: 21.9M Q4 '22 — Operating Cash Flow: -49.7M Q4 '22 — Free Cash Flow: -50.3M Q4 '22 — Net Income: -42.7M Q1 '23 — Revenue: 71.4M Q1 '23 — Operating Cash Flow: -5.1M Q1 '23 — Free Cash Flow: -5.3M Q1 '23 — Net Income: 1.6M Q2 '23 — Revenue: 98.2M Q2 '23 — Operating Cash Flow: 8.6M Q2 '23 — Free Cash Flow: 8.3M Q2 '23 — Net Income: 22.1M Q3 '23 — Revenue: 102.7M Q3 '23 — Operating Cash Flow: -5.2M Q3 '23 — Free Cash Flow: -5.5M Q3 '23 — Net Income: 20.9M Q4 '23 — Revenue: 108.4M Q4 '23 — Operating Cash Flow: 13.6M Q4 '23 — Free Cash Flow: 13.2M Q4 '23 — Net Income: 4.7M Q1 '24 — Revenue: 88.6M Q1 '24 — Operating Cash Flow: -489K Q1 '24 — Free Cash Flow: -556K Q1 '24 — Net Income: -118.8M Q2 '24 — Revenue: -1M Q2 '24 — Operating Cash Flow: -66.6M Q2 '24 — Free Cash Flow: -66.7M Q2 '24 — Net Income: -72.7M Q3 '24 — Revenue: 416K Q3 '24 — Operating Cash Flow: -41.6M Q3 '24 — Free Cash Flow: -41.6M Q3 '24 — Net Income: -72.7M Q4 '24 — Revenue: -665K Q4 '24 — Operating Cash Flow: -59M Q4 '24 — Free Cash Flow: -59M Q4 '24 — Net Income: -37.5M Q1 '25 — Revenue: 0 Q1 '25 — Operating Cash Flow: -39.8M Q1 '25 — Free Cash Flow: -39.8M Q1 '25 — Net Income: -35.9M Q2 '25 — Revenue: 0 Q2 '25 — Operating Cash Flow: -25.2M Q2 '25 — Free Cash Flow: -25.3M Q2 '25 — Net Income: -41.4M Q3 '25 — Revenue: 0 Q3 '25 — Operating Cash Flow: -30.4M Q3 '25 — Free Cash Flow: -30.4M Q3 '25 — Net Income: -34.4M Q4 '25 — Revenue: 0 Q4 '25 — Operating Cash Flow: -27.9M Q4 '25 — Free Cash Flow: -28M Q4 '25 — Net Income: -33M Q1 '26 — Operating Cash Flow: -36.9M Q1 '26 — Net Income: -41.3M Q2 '26 — Operating Cash Flow: -31.4M Q2 '26 — Net Income: -43.4M -100M -50M 0 50M 100M 150M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-12-31, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.5
Accruals -9.6%
ROA -57.5%
ROCE -66.6%
ROE -63.6%
Asset turnover —
Capex / sales —
EBITDA margin —
FCF margin —
Gross margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
ROIC —
SBC / sales —

0 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

2.1
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.1
Current ratio 12.1×
ND/EBITDA —
Cash runway 2.0 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 10.3×
F-score 3.4 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales CAGR 4Y -100.0%
Sales/sh Y/Y -100.0%
Sales Q/Q -100.0%
Shares change +38.8%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.